person · Reporting owner

RAAB MICHAEL

Disclosed activity across 3 companies

Tapewire entity: 19876
SEC CIK: 0001321402

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARDELYX, INC.ARDX · Entity 4972	Director · President & CEO	August 21, 2026	August 25, 2026
Tempest Therapeutics, Inc.TPST · Entity 7734	Director	January 27, 2026	January 28, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARDELYX, INC.

Report date August 21, 2026 · Filed August 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,619,792	Ending reported balance After 2026-08-21 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-08-21 · Sale · Disposed 15,009 · Balance 1,663,357 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 2 · 2026-08-21 · Sale · Disposed 15,976 · Balance 1,647,381 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2026-08-21 · Sale · Disposed 8,411 · Balance 1,638,970 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 4 · 2026-08-21 · Sale · Disposed 19,178 · Balance 1,619,792 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Common StockSEC Table I · non-derivative	IndirectFamily Trust	24,364	Reported balance Holding disclosure · report date 2026-08-21 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 24,364 F2: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012.
Common StockSEC Table I · non-derivative	IndirectFamily Trust	1,000	Reported balance Holding disclosure · report date 2026-08-21 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 1,000 F3: The shares are owned directly by trusts for the benefit of the Reporting Person's children.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012.

F3: The shares are owned directly by trusts for the benefit of the Reporting Person's children.

Tempest Therapeutics, Inc.

Report date January 27, 2026 · Filed January 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2036-01-26	Direct	1,230	Reported balance After 2026-01-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-27 · Grant · Acquired 1,230 · Balance 1,230 F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AMICUS THERAPEUTICS, INC.

Report date April 27, 2026 · Filed April 27, 2026

Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-04-27 transaction · row 1 1 source row Row 1 · 2026-04-27 · Disposition to issuer · Disposed 115,857 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 95,443 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.71 · Expires 2026-06-09	Direct	Reported balance After 2026-04-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2027-06-13	Direct	Reported balance After 2026-04-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-27 · Disposition to issuer · Disposed 16,236 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2029-06-27	Direct	Reported balance After 2026-04-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-04-27 · Disposition to issuer · Disposed 19,473 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.81 · Expires 2030-06-04	Direct	Reported balance After 2026-04-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-04-27 · Disposition to issuer · Disposed 18,574 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10	Direct	Reported balance After 2026-04-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-04-27 · Disposition to issuer · Disposed 36,111 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09	Direct	Reported balance After 2026-04-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08	Direct	Reported balance After 2026-04-27 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06	Direct	Reported balance After 2026-04-27 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05	Direct	Reported balance After 2026-04-27 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 95,443 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).

F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.

F3: Each Option was fully vested.

F4: Each Option vested in full in connection with consummation of the Merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 10, 2021 Filed Jun 14, 2021 23:09 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	10,115	$0.00	$0.00	Disclosure SEC source: 0001209191-21-040384 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,749 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document
May 20, 2021 Filed May 21, 2021 20:47 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	2,534	$7.09	$17,960.49	Disclosure SEC source: 0001567619-21-010922 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,754 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
May 18, 2021 Filed May 20, 2021 21:03 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	5,634	$0.00 Strike: $7.56	$0.00	Disclosure SEC source: 0001209191-21-034478 · doc4.xml · derivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,634 shares Expires 2021-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the options were fully vested and exercisable as of the transaction date. Read SEC document
May 18, 2021 Filed May 20, 2021 21:03 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionCommon Stock	5,634	$7.56	$42,593.04	Disclosure SEC source: 0001209191-21-034478 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 22, 2021 Filed Feb 24, 2021 21:39 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	2,534	$6.88	$17,440.26	Disclosure SEC source: 0001567619-21-004773 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,288 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
January 05, 2021 Filed Jan 8, 2021 00:13 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	517,959	$0.00 Strike: $6.35	$0.00	Disclosure SEC source: 0001567619-21-000767 · doc1.xml · derivative · entry 4 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,959 Underlying: Common Stock · 517,959 shares Expires 2031-01-05 F4 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2021, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
January 05, 2021 Filed Jan 8, 2021 00:13 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	115,102	$0.00	$0.00	Disclosure SEC source: 0001567619-21-000767 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,822 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document
September 15, 2020 Filed Sep 17, 2020 22:31 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	106,337	$5.61	$596,284.73	Disclosure SEC source: 0001567619-20-016847 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,720 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: The transaction was executed in multiple trades in prices ranging from $5.30 to $5.78, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan on August 31, 2020. Read SEC document
July 02, 2020 Filed Jul 6, 2020 20:47 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	23,128	$7.01	$162,129.59	Disclosure SEC source: 0001567619-20-012966 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 24,364 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 21, 2019. F2 · price: The transaction was executed in multiple trades in prices ranging from $7.00 to $7.0650, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012. Read SEC document
June 10, 2020 Filed Jun 12, 2020 21:25 UTC	ARDELYX, INC. ARDX · Entity 4972	OtherCommon Stock	1,235	$0.00	$0.00	Disclosure SEC source: 0001567619-20-012107 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 47,492 F1 · kind: Pro rata distribution from NEA Partners 12, Limited Partnership, of which the reporting person is a limited partner. F2 · ownership.nature: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012. Read SEC document
June 04, 2020 Filed Jun 8, 2020 20:58 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	18,574	$0.00 Strike: $12.81	$0.00	Disclosure SEC source: 0001209191-20-035006 · doc4.xml · derivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,574 Underlying: Common Stock · 18,574 shares Expires 2030-06-04 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document
June 04, 2020 Filed Jun 8, 2020 20:58 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	5,855	$0.00	$0.00	Disclosure SEC source: 0001209191-20-035006 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document
June 01, 2020 Filed Jun 2, 2020 22:38 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	23,128	$7.33	$169,634.63	Disclosure SEC source: 0001567619-20-011554 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 46,257 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 21, 2019. F2 · price: The transaction was executed in multiple trades in prices ranging from $7.17 to $7.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012. Read SEC document
June 01, 2020 Filed Jun 4, 2020 01:09 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	5,000	$0.00 Strike: $2.81	$0.00	Disclosure SEC source: 0001209191-20-034325 · doc4.xml · derivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options were fully vested and exercisable as of June 1, 2020. Read SEC document
June 01, 2020 Filed Jun 4, 2020 01:09 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	SaleCommon Stock	5,000	$12.65	$63,260.50	Disclosure SEC source: 0001209191-20-034325 · doc4.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,145 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.33 to $12.89 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 01, 2020 Filed Jun 4, 2020 01:09 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionCommon Stock	5,000	$2.81	$14,050.00	Disclosure SEC source: 0001209191-20-034325 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 05, 2020 Filed May 5, 2020 22:11 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	4,486	$7.03	$31,536.13	Disclosure SEC source: 0001567619-20-009078 · doc1.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 69,385 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 21, 2019. F4 · price: The transaction was executed in multiple trades in prices ranging from $7.00 to $7.1050, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012. Read SEC document
May 04, 2020 Filed May 5, 2020 22:11 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	15,941	$7.01	$111,685.83	Disclosure SEC source: 0001567619-20-009078 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 73,871 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 21, 2019. F2 · price: The transaction was executed in multiple trades in prices ranging from $7.00 to $7.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012. Read SEC document
April 17, 2020 Filed Apr 18, 2020 00:01 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	9,428	$7.02	$66,168.53	Disclosure SEC source: 0001567619-20-008137 · doc1.xml · nonDerivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 89,812 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 21, 2019. F4 · price: The transaction was executed in multiple trades in prices ranging from $7.00 to $7.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012. Read SEC document
April 16, 2020 Filed Apr 18, 2020 00:01 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	10,500	$7.01	$73,641.75	Disclosure SEC source: 0001567619-20-008137 · doc1.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 99,240 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 21, 2019. F3 · price: The transaction was executed in multiple trades in prices ranging from $7.00 to $7.0450, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · ownership.nature: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012. Read SEC document
April 15, 2020 Filed Apr 18, 2020 00:01 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	500	$7.03	$3,515.00	Disclosure SEC source: 0001567619-20-008137 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 109,740 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 21, 2019. F2 · ownership.nature: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012. Read SEC document
March 02, 2020 Filed Mar 5, 2020 01:12 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionStock Option (Right to Buy) · Derivative	11,123	$0.00 Strike: $1.08	$0.00	Disclosure SEC source: 0001567619-20-005668 · doc1.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,123 shares Expires 2020-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document
March 02, 2020 Filed Mar 5, 2020 01:12 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	20,428	$7.01	$143,284.03	Disclosure SEC source: 0001567619-20-005668 · doc1.xml · nonDerivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 110,240 F3 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 21, 2019. F4 · price: The transaction was executed in multiple trades in prices ranging from $7.00 to $7.065, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F5 · ownership.nature: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012. Read SEC document
March 02, 2020 Filed Mar 5, 2020 01:12 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	11,123	$7.00	$77,861.00	Disclosure SEC source: 0001567619-20-005668 · doc1.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,057 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 23, 2019. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,229 shares under the Ardelyx Employee Stock Purchase Plan on February 28, 2020. Read SEC document
March 02, 2020 Filed Mar 5, 2020 01:12 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionCommon Stock	11,123	$1.08	$12,012.84	Disclosure SEC source: 0001567619-20-005668 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 23, 2019. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,229 shares under the Ardelyx Employee Stock Purchase Plan on February 28, 2020. Read SEC document
February 05, 2020 Filed Feb 7, 2020 23:49 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $1.08	$0.00	Disclosure SEC source: 0001567619-20-002467 · doc1.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,123 Underlying: Common Stock · 25,000 shares Expires 2020-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document
February 05, 2020 Filed Feb 7, 2020 23:49 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	25,000	$7.32	$182,927.50	Disclosure SEC source: 0001567619-20-002467 · doc1.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,828 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 23, 2019. F4 · price: This transaction was executed in multiple trades in prices ranging from $7.19 to $7.45, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Reflects the adjusted total which includes the purchase of 2,310 shares under the Ardelyx Employee Stock Purchase Plan on August 31, 2019 F3 · balance_after: Reflects the transfer of 49,837 shares previously held directly by the reporting person into a family trust. Read SEC document
February 05, 2020 Filed Feb 7, 2020 23:49 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionCommon Stock	25,000	$1.08	$27,000.00	Disclosure SEC source: 0001567619-20-002467 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 23, 2019. F2 · balance_after: Reflects the adjusted total which includes the purchase of 2,310 shares under the Ardelyx Employee Stock Purchase Plan on August 31, 2019 F3 · balance_after: Reflects the transfer of 49,837 shares previously held directly by the reporting person into a family trust. Read SEC document
January 09, 2020 Filed Jan 13, 2020 23:39 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option · Derivative	557,460	$0.00 Strike: $7.60	$0.00	Disclosure SEC source: 0001567619-20-000947 · doc1.xml · derivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 557,460 Underlying: Common Stock · 557,460 shares Expires 2030-01-09 F1 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 9, 2020, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
June 27, 2019 Filed Jul 1, 2019 21:01 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	19,473	$0.00 Strike: $12.00	$0.00	Disclosure SEC source: 0001209191-19-039769 · doc4.xml · derivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,473 Underlying: Common Stock · 19,473 shares Expires 2029-06-27 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2020. Read SEC document
June 27, 2019 Filed Jul 1, 2019 21:01 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	6,250	$0.00	$0.00	Disclosure SEC source: 0001209191-19-039769 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,145 F1 · shares: The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics, Inc. common stock. Read SEC document
June 04, 2019 Filed Jun 7, 2019 01:11 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	10,054	$2.54	$25,551.24	Disclosure SEC source: 0001567619-19-012995 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,355 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $2.5200 to $2.5745, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan on February 28, 2019. Read SEC document
June 03, 2019 Filed Jun 4, 2019 20:35 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	5,000	$0.00 Strike: $7.15	$0.00	Disclosure SEC source: 0001209191-19-034296 · doc4.xml · derivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 5,000 shares Expires 2019-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options were fully vested and exercisable as of June 3, 2019. Read SEC document
June 03, 2019 Filed Jun 4, 2019 20:35 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	SaleCommon Stock	5,000	$11.16	$55,776.00	Disclosure SEC source: 0001209191-19-034296 · doc4.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,895 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 15, 2019. F2 · price: The price is the weighted average price for the transactions report on this line. The prices for the transactions reported on this line range from $10.98 to $11.32 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 03, 2019 Filed Jun 4, 2019 20:35 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionCommon Stock	5,000	$7.15	$35,750.00	Disclosure SEC source: 0001209191-19-034296 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 17, 2019 Filed Jan 22, 2019 22:06 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option · Derivative	455,000	$0.00 Strike: $2.32	$0.00	Disclosure SEC source: 0001567619-19-001441 · doc1.xml · derivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,000 Underlying: Common Stock · 455,000 shares Expires 2029-01-17 F1 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 17, 2019, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
January 02, 2019 Filed Jan 5, 2019 00:11 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	19,644	$1.70	$33,418.37	Disclosure SEC source: 0001567619-19-000642 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,409 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $1.70 to $1.7256, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Shares held after the transaction reflects the prior transfer of an aggregate of 11,446, previously held directly by the Reporting Person, into the Reporting Person's trust. Read SEC document
November 13, 2018 Filed Nov 15, 2018 22:41 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	6,539	$2.84	$18,570.76	Disclosure SEC source: 0001567619-18-006487 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,499 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $2.8022 to $2.84, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
July 26, 2018 Filed Jul 30, 2018 23:50 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	185,000	$0.00 Strike: $4.30	$0.00	Disclosure SEC source: 0001140361-18-034303 · doc1.xml · derivative · entry 4 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2028-07-26 F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/48 of the shares subject thereto on each monthly anniversary of July 26, 2018, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
July 26, 2018 Filed Jul 30, 2018 23:50 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	200,000	$0.00	$0.00	Disclosure SEC source: 0001140361-18-034303 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,038 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document
June 07, 2018 Filed Jun 11, 2018 20:39 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	8,912	$0.00 Strike: $16.23	$0.00	Disclosure SEC source: 0001209191-18-036989 · doc4.xml · derivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,912 Underlying: Common Stock · 8,912 shares Expires 2028-06-07 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2019. Read SEC document
June 07, 2018 Filed Jun 11, 2018 20:39 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	3,081	$0.00	$0.00	Disclosure SEC source: 0001209191-18-036989 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,895 F1 · shares: The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics, Inc. common stock. Read SEC document
April 16, 2018 Filed Apr 18, 2018 22:03 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	5,000	$0.00 Strike: $10.53	$0.00	Disclosure SEC source: 0001209191-18-025444 · doc4.xml · derivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2018-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options were fully vested and exercisable as of April 16, 2018. Read SEC document
April 16, 2018 Filed Apr 18, 2018 22:03 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	SaleCommon Stock	5,000	$14.41	$72,057.50	Disclosure SEC source: 0001209191-18-025444 · doc4.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,814 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2018. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.39 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
April 16, 2018 Filed Apr 18, 2018 22:03 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionCommon Stock	5,000	$10.53	$52,650.00	Disclosure SEC source: 0001209191-18-025444 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 16, 2018 Filed Jan 19, 2018 00:50 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	390,348	$0.00 Strike: $7.10	$0.00	Disclosure SEC source: 0001140361-18-002462 · doc1.xml · derivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,348 Underlying: Common Stock · 390,348 shares Expires 2028-01-16 F1 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 16, 2018, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
January 02, 2018 Filed Jan 4, 2018 22:14 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	4,366	$0.00 Strike: $7.51	$0.00	Disclosure SEC source: 0001209191-18-002065 · doc4.xml · derivative · entry 4 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,634 Underlying: Common Stock · 4,366 shares Expires 2021-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document
January 02, 2018 Filed Jan 4, 2018 22:14 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	5,000	$0.00 Strike: $2.81	$0.00	Disclosure SEC source: 0001209191-18-002065 · doc4.xml · derivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2020-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document
January 02, 2018 Filed Jan 4, 2018 22:14 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	SaleCommon Stock	9,366	$15.00	$140,490.00	Disclosure SEC source: 0001209191-18-002065 · doc4.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,814 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. F3 · price: This price of $15.00 is the sole sale price for the transactions reported on this line. Read SEC document
January 02, 2018 Filed Jan 4, 2018 22:14 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionCommon Stock	9,366	$15.00	$140,490.00	Disclosure SEC source: 0001209191-18-002065 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. F2 · price: This price of $15.00 is the sole purchase price for the transactions reported on this line. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.